Mishra et al. evaluated the use of eprenetapopt IV 3.7 g once daily on days 1 to 4 with azacitidine injections 36 mg/m2 once daily from days 1 to 5 of a 28 day cycle in TP53-mutated AML and MDS patients as a post-transplant maintenance regimen and reported that the 1-year RFS of 60% has met their prespecified hypothesis of ≥50%, as historical data correspond to 30% RFS [55]. This evidence concerns the gene TP53 and myelodysplastic syndrome.